Moxifloxacin punctal plug - Ocular Therapeutix

Drug Profile

Moxifloxacin punctal plug - Ocular Therapeutix

Alternative Names: Moxifloxacin sustained-release - Ocular Therapeutix; OTX-MP

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ocular Therapeutix
  • Class Antibacterials; Azabicyclo compounds; Cyclopropanes; Fluoroquinolones; Piperidines; Pyrrolidines; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Conjunctivitis

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Conjunctivitis in Singapore (Ophthalmic, Controlled release)
  • 20 May 2015 Pharmacokinetics and adverse events data from a phase I trial in Conjunctivitis (Bacterial conjunctivitis in post-cataract surgery patients) released by Ocular Therapeutix before May 2015 (Ocular Therapeutix From S-1; May 2015)
  • 20 May 2015 Ocular Therapeutix plans a phase II trial in Conjunctivitis (Bacterial conjunctivitis) in USA (Ocular Therapeutix From S-1; May 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top